Brian Elsbernd is Chief Compliance/Legal Officer at CATALYST PHARMACEUTICALS, INC. (CPRX). They have made 7 open-market trades across 1 company since 2022, most recently 2025-12-29.
CIK 0001763511
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CPRX | 245,124 | $7.7M |
Shares reported on the most recent Form 4, priced at the 2025-12-30 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CPRX | SELL · Routine | 2025-11-12 | 2025-11-14 | $22.70 | $908K | +0.9% | +4.2% | +1.7% |
| CPRX | SELL | 2025-09-08 | 2025-09-10 | $20.30 | $609K | +1.3% | +2.9% | +13.9% |
| CPRX | SELL | 2025-09-03 | 2025-09-05 | $19.84 | $1.4M | -1.2% | +2.3% | +13.9% |
| CPRX | SELL | 2025-03-03 | 2025-03-05 | $22.98 | $2.9M | +0.8% | +6.6% | +15.1% |
| CPRX | SELL | 2024-11-26 | 2024-11-29 | $21.62 | $372K | -0.6% | -4.7% | -2.0% |
| CPRX | SELL | 2024-03-27 | 2024-03-28 | $16.44 | $822K | +0.6% | -3.5% | -4.5% |
| CPRX | SELL | 2023-03-20 | 2023-03-22 | $16.07 | $804K | +2.9% | +0.1% | -23.4% |
| CPRX | SELL | 2022-11-11 | 2022-11-15 | $16.24 | $476K | +4.1% | +6.3% | -1.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.